Skip to main navigation
Acadia
  • Home
  • Contact
  • Home
  • About
    • Management Team
    • Board Of Directors
    • Our Purpose, Mission & Values
    • History
  • Product
  • Pipeline
    • Dementia-Related Psychosis
    • Rett syndrome
    • Schizophrenia – Negative Symptoms
    • Early Stage Clinical Programs
  • Resources
    • Parkinson’s Disease Psychosis
    • Clinical Trials
    • Investigator Initiated Trials
    • Medical Education Grants
    • Scientific Publications
  • Partnering
  • Investors
    • Stock Information
    • News Releases
    • Events & Presentations
    • Sec Filings
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • Annual Report and Proxy
    • Information Request
    • Email Alerts
  • Media
  • Careers
  • Contact
  • About
    • Management Team
    • Board Of Directors
    • Our Purpose, Mission & Values
    • History
  • Product
  • Pipeline
    • Dementia-Related Psychosis
    • Rett Syndrome
    • Schizophrenia – Negative Symptoms
    • Early Stage Clinical Programs
  • Resources
    • Parkinson’s Disease Psychosis
    • Clinical Trials
    • Investigator Initiated Trials
    • Medical Education Grants
    • Scientific Publications
  • Partnering
  • Investors
    • Stock Information
    • News Releases
    • Events & Presentations
    • SEC Filings
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • Annual Report and Proxy
    • Information Request
    • Email Alerts
  • Media
  • Careers

Media Center

Recent News

03/08/21
Summary ToggleAcadia Pharmaceuticals Provides Regulatory Update on Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
02/24/21
Summary ToggleAcadia Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
02/19/21
Summary ToggleAcadia Pharmaceuticals Recognizes National Caregiver’s Day with Launch of MoreThanMemoryLoss.com
02/18/21
Summary ToggleAcadia Pharmaceuticals to Present at Upcoming Investor Conferences
02/10/21
Summary ToggleAcadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
2020 | 2019 | 2018 | Archive
  • COMPANY FACTS
  • Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research we are exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders.
  • Headquartered in San Diego, California
  • R&D Center, Princeton, New Jersey
  • Stock is listed on NASDAQ: ACAD
  • Chief Executive Officer:
    Stephen R. Davis
  • Media Contact

Shareholder Tools

  • Print Page
  • RSS Feeds
  • Share
  • Privacy
  • Cookies
  • Privacy
    Shield
  • Terms
  • Email

© 2021 Acadia Pharmaceuticals Inc. Acadia and NUPLAZID are registered
trademarks of Acadia Pharmaceuticals Inc. All rights reserved.

This website uses cookies to improve and customize your experience on our website. By using this website without changing your cookie settings in your browser, you agree to our use of cookies. For further details on cookies, how we use cookies and how to delete or block the use of cookies, please read our Cookie Policy.

ACCEPT